| [1] |
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference [J]. Diabetes Care, 2014, 37(10): 2864-83.
|
| [2] |
Kirsztajn GM, Filho NS, Draibe SA, et al. Fast reading of the KDIGO 2012: guidelines for evaluation and management of chronic kidney disease in clinical practice] [J]. J Brasil Nefrol, 2014, 36(1): 63-73.
|
| [3] |
Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy [J]. J Am Soc Nephrol, 2010, 21(4): 556-563.
|
| [4] |
Cherney DZ, Perkins BA, Soleyanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus [J]. Circulation, 2014, 129(5): 587-597.
|
| [5] |
Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction [J]. Diabetes Care, 2013, 36(11): 3460-3468.
|
| [6] |
Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen [J]. Diabetes, 2014, 63(6): 2120-2131.
|
| [7] |
Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial [J]. JAMA, 2015, 314(9): 884-894.
|
| [8] |
Chin MP, Reisman SA, Bakris GL, et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl [J]. Am J Nephrol, 2014, 39(6): 499-508.
|
| [9] |
Baumann M, Burkhardt K, Heemann U. Microcirculatory marker for the prediction of renal end points: a prospective cohort study in patients with chronic kidney disease stage 2 to 4 [J]. Hypertension (Dallas, Tex : 1979), 2014, 64(2): 338-346.
|
| [10] |
Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease [J]. New Engl J Med, 2013, 369(23): 2183-2196.
|
| [11] |
Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial [J]. Lancet (London, England), 2010, 375(9721): 1173-1181.
|
| [12] |
Odden MC, Amadu AR, Smit E, et al. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002 [J]. Am J Kidney Dis, 2014, 64(4): 550-557.
|
| [13] |
Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney [J]. Pediatr Nephrol (Berlin, Germany), 2014, 29(6): 999-1008.
|
| [14] |
Bridgeman MB, Chavez B. Febuxostat for the treatment of gout [J]. Expert Opin Pharmacother, 2015, 16(3): 395-398.
|
| [15] |
Hattori M, Nikolic-Paterson DJ, Miyazaki K, et al. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury [J]. Kidney Int Suppl, 1999, 71: S47-S50.
|
| [16] |
Kastorini CM, Milionis HJ, Espositio K, et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534，906 individuals [J]. J Am Coll Cardiol, 2011, 57(11): 1299-1313.
|